Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIB-626 in Mild Alzheimer's Disease Dementia
NCT05040321Phase 2Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Dec 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of liposomal β-nicotinamide mononucleotide in Alzheimer's disease (AD), sponsored by Brigham and Women's Hospital. Started Dec 2021; status: completed.
02
Drugs
liposomal β-nicotinamide mononucleotide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05040321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05040321.